

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FRONTAGE HOLDINGS CORPORATION

方達控股公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1521)

RESIGNATION OF NON-EXECUTIVE DIRECTOR APPOINTMENT OF NON-EXECUTIVE DIRECTORS, CHANGE IN COMPOSITION OF AUDIT AND RISK MANAGEMENT COMMITTEE AND CHANGE OF AUTHORISED REPRESENTATIVE

The Board is pleased to announce that with effect from June 1, 2022:

1. Mr. Jun Gao has resigned as a non-executive Director and a member of the Audit and Risk Management Committee;
2. Ms. Yin Zhuan has been appointed as a non-executive Director;
3. Mr. Hao Wu has been appointed as a non-executive Director and a member of the Audit and Risk Management Committee; and
4. Dr. Song Li has replaced Dr. Zhihe Li as an Authorised Representative.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Frontage Holdings Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Jun Gao (“**Mr. Gao**”) has resigned as a non-executive Director with effect from June 1, 2022 in order to devote more time to his other commitments. Following Mr. Gao’s resignation as a non-executive Director, he has also ceased to be a member of the audit and risk management committee of the Board (the “**Audit and Risk Management Committee**”).

Mr. Gao has confirmed that he has no disagreement with the Board and there is no matter in relation to the resignation that needs to be brought to the attention to the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Gao for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS

The Board is pleased to announce that Ms. Yin Zhuan (“**Ms. Yin**”) and Mr. Hao Wu (“**Mr. Wu**”) have been appointed as non-executive Directors with effect from June 1, 2022. Mr. Wu has also been appointed as a member of the Audit and Risk Committee with effect from June 1, 2022.

The biographical details of Ms. Yin and Mr. Wu are set out below:

Ms. Yin, aged 56, is currently, and has been since April 2020 and September 2010, an executive director and deputy general manager, respectively, of Hangzhou Tigermed Consulting Co., Ltd. (“**Hangzhou Tigermed**”, a company listed on the Hong Kong Stock Exchange with stock code 3347 and the Shenzhen Stock Exchange with stock code 300347), a controlling shareholder of the Company. Ms. Yin is primarily responsible for overseeing the data management and statistical analysis businesses of Hangzhou Tigermed. Ms. Yin has 29 years of experience in the field of biostatistics and has extensive management experience. She also has considerable experience regarding the review of new drugs, particularly cancer-related drugs. Prior to joining Hangzhou Tigermed, Ms. Yin served at AstraZeneca LP as a biostatistician, senior biostatistician and associate director of biostatistician from 1995 to 2003. Ms. Yin founded and served as the chairman or executive director of MacroStat from October 2005 to November 2009. Ms. Yin received her bachelor’s degree in law from Fudan University (復旦大學) in July 1988 and obtained her master’s degree of science from the University of Massachusetts in September 1993.

Mr. Wu (吳灝), aged 54, is currently, and has been since January 2020, an executive director and the co-president of Hangzhou Tigermed. Mr. Wu has over 17 years of experience in the pharmaceutical industry and has extensive marketing and managerial experience. Prior to joining Hangzhou Tigermed in January 2020, Mr. Wu served successively as sales manager and a product/project manager of Schering Plough Pharmaceutical Co., Ltd.* (先靈葆雅製藥有限公司) from August 1994 to October 1999, product manager of Shanghai Roche Pharmaceutical Co., Ltd.* (上海羅氏製藥有限公司) from October 1999 to December 2002, marketing director of Eisai China Inc.* (衛材(中國)製藥有限公司) from January 2003 to July 2007, director of marketing and business development department of SciClone International Pharmaceutical Co., Ltd.* (賽生國際製藥有限公司) from August 2007 to January 2009 and the general manager of Meixin Insurance Broker (Shanghai) Co., Ltd. (美信保險經紀(上海)有限公司) from March 2010 to January 2020. Mr. Wu obtained his bachelor’s degree in clinical medicine from Shanghai Jiao Tong University School of Medicine (formerly known as Shanghai Second Medical University) in 1992 and an EMBA degree from China Europe International Business School in 2009.

Each of Ms. Yin and Mr. Wu has entered into a letter of appointment with the Company for an initial term of three years commencing from June 1, 2022, which can be terminated by either party giving to the other not less than three months’ prior notice in writing. Ms. Yin and Mr. Wu will hold office until the next annual general meeting of the Company at which they will be eligible for the re-election. Thereafter, Ms. Yin and Mr. Wu will be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company. Pursuant to the letter of appointment, each of Ms. Yin and Mr. Wu is entitled to an annual director’s fee of RMB100,000, which is determined by the Board based on the recommendation of the remuneration committee of the Board with reference to the Company’s performance, his/her duties and responsibilities with the Company and prevailing market conditions.

Save as disclosed above, as at the date of this announcement, each of Ms. Yin and Mr. Wu (i) does not have any interests in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not hold any other directorships in any other public companies the securities of which are listed in Hong Kong or overseas in the last three years; (iii) does not hold any other position with the Company and other members of the Group; (iv) does not have other major appointments and professional qualifications; and (v) does not have any relationships with any Directors, senior management, substantial or controlling shareholders of the Company (each as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

Save as disclosed above, there is no other information relating to Ms. Yin and Mr. Wu which is required to be disclosed pursuant to Rules 13.51(2) of the Listing Rules, nor are there any other matters relating to the appointment of Ms. Yin and Mr. Wu that need to be brought to the attention of the Shareholders.

The Board would like to extend its welcome to Ms. Yin and Mr. Wu for joining the Company.

CHANGE IN COMPOSITION OF AUDIT AND RISK MANAGEMENT COMMITTEE

The Board announces that Mr. Wu has been appointed as a member of the Audit and Risk Management Committee with effect from June 1, 2022.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board further announces that Dr. Song Li, an executive Director, chairman of the Board and the Chief Executive Officer of the Company, has been appointed as an authorised representative of the Company (the “**Authorised Representative**”) in replacement of Dr. Zhihe Li for the purpose of Rule 3.05 of the Listing Rules with effect from June 1, 2022. Dr. Zhihe Li remains as an executive Director after he has ceased to be the Authorised Representative. Ms. Karen Ying Lung Chang remains as the other Authorised Representative.

By Order of the Board
Frontage Holdings Corporation
Dr. Song Li
Chairman

Hong Kong, June 1, 2022

As at the date of this announcement, the Board comprises Dr. Song Li and Dr. Zhihe Li as executive directors; Ms. Yin Zhuan and Mr. Hao Wu as non-executive directors; and Mr. Yifan Li, Mr. Erh Fei Liu and Dr. Jingsong Wang as independent non-executive directors.

* *For identification purpose only*